Febuxostat for the management of hyperuricaemia in people with gout

NICE technology appraisals [TA164] Published date:

Febuxostat is recommended as a possible treatment for chronic hyperuricaemia in people with gout only if:

  • they can't take the medicine allopurinol for medical reasons or
  • the side effects of allopurinol are so bad that the person either has to stop taking it or can't be given the most effective dose.

People who were already taking febuxostat when the guidance was issued should be able to carry on taking it until they and their healthcare professional(s) decide that it is the right time to stop treatment.

 

Get involved